Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60 in the latest trading session, marking a +0.8% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.67%. On the other hand, the Dow registered a gain of 1.07%, and the technology-centric Nasdaq increased by 2.5%.Coming into today, shares of the company had gained 5.9% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.The upcoming earnings release of Ginkgo Bioworks Holdi ...

Exclusive: As genetic testing company 23andMe seeks to sell the consumer data of millions of Americans as part of its bankruptcy proceedings, Senate HELP Committee Chairman Bill Cassidy is opening up a probe into the company to ensure that users' medical data and DNA do not fall into the wrong hands. In a pair of letters obtained by FOX Business, Cassidy, R-La., raised concerns with Treasury Secretary Scott Bessent and 23andMe executives over the risk that Chinese companies or other foreign adversaries may ...

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision. Here's Why DNA Could Experience a Turnaround Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining 28.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earn ...

24/7 Market News- Kraig Labs Makes History: World Record DNA Insertion Unlocks Massive PotentialMarch 27, 2025 10:31 AM EDT | Source: 24/7 Market NewsDenver, Colorado--(Newsfile Corp. - March 27, 2025) -  247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Kraig Biocraft Laboratories' (OTCQB: KBLB) ("Kraig Labs") groundbreaking achievement-successfully inserting the largest functional DNA construct e ...

Core Points - 23andMe has filed for Chapter 11 bankruptcy protection, leading to concerns about the future of customer genetic data [4][6] - The company's co-founder and CEO, Anne Wojcicki, has resigned and plans to bid on the company during the bankruptcy sale process [5] - Privacy experts are advising users to consider deleting their data due to potential risks from new ownership and hackers [3][7] Company Situation - The bankruptcy filing aims to facilitate the sale of substantially all assets and reduce operational costs by rejecting certain lease contracts [6] - 23andMe intends to continue operations during the bankruptcy process [6] - The company has faced previous data breaches, including a 2023 incident that exposed the genetic data of nearly 7 million customers [8] Data Privacy Concerns - Experts highlight the sensitivity and value of genetic data, emphasizing that it is unique to each individual [9][10] - 23andMe claims it does not share data with health insurance companies or employers without user consent, but there are concerns about how data can still be used for targeted advertising [10][11] - California Attorney General has issued alerts regarding users' rights to delete their data amid the company's financial distress [12] User Data Management - Users can delete their data by accessing account settings and following specific steps to confirm deletion [13] - Users can also request the destruction of their saliva samples and withdraw consent for third-party research [14]

DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company’s more than 15 million customers.The former Silicon Valley darling sought Chapter 11 protection on Sunday after struggling with weak demand for its ancestry testing kits that once featured in Oprah Winfrey’s annual list of favorite things, and following a 2023 data breach that damaged its reputation. 7 DNA testing pioneer 23andMe, one of Silicon Valley’s most recognized biotech st ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed the latest trading day at $7.27, indicating a +1.39% change from the previous session's end. The stock exceeded the S&P 500, which registered a gain of 0.08% for the day. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq increased by 0.52%.Coming into today, shares of the company had lost 37.27% in the past month. In that same time, the Medical sector lost 1.03%, while the S&P 500 lost 7.33%.Investors will be eagerly watching ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been beaten down lately with too much selling pressure. While the stock has lost 52.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum ...

Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!TechCrunch’s transportation team — well at least myself and senior reporter Rebecca Bellan — are hittin’ the road. Destination: SXSW, the annual tech, music, film, and culture conference in Austin. We both have panels and if you’re at SXSW, please come check these out and introduce yourself.  We’ll be keeping our eyes and ears open for transpor ...

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - Ginkgo Bioworks is projected to earn -$5.06 per share for the fiscal year ending December 2025, reflecting a 51.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Ginkgo Bioworks has increased by 17.7%, indicating a positive trend in earnings estimates [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which subsequently affects stock prices [5]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Ginkgo Bioworks to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].